In the current research, we obtained three public RNA-seq datasets from immunotherapy cohorts to identify novel biomarkers for immunotherapy, and reported that CD2, HAVCR2, HLA-C, HLA-DRA, HLA-E, KLRK1, and TYROBP might be novel biomarkers for immunotherapy in NSCLC. Here, CD2 is linked to non-small cell lung carcinoma.